Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Receivables (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Change in Receivables for 8 consecutive years, with $20.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 178.34% year-over-year to $20.1 million, compared with a TTM value of $61.0 million through Dec 2025, up 409.96%, and an annual FY2025 reading of $61.0 million, up 409.96% over the prior year.
  • Change in Receivables was $20.1 million for Q4 2025 at Catalyst Pharmaceuticals, down from $40.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $40.5 million in Q3 2025 and bottomed at -$5.4 million in Q2 2025.
  • Average Change in Receivables over 5 years is $6.0 million, with a median of $2.5 million recorded in 2022.
  • Peak annual rise in Change in Receivables hit 18466.67% in 2022, while the deepest fall reached 239.65% in 2022.
  • Year by year, Change in Receivables stood at -$6000.0 in 2021, then skyrocketed by 18466.67% to $1.1 million in 2022, then surged by 395.92% to $5.5 million in 2023, then skyrocketed by 31.93% to $7.2 million in 2024, then surged by 178.34% to $20.1 million in 2025.
  • Business Quant data shows Change in Receivables for CPRX at $20.1 million in Q4 2025, $40.5 million in Q3 2025, and -$5.4 million in Q2 2025.